{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T10:27:51Z","timestamp":1791973671452,"version":"4.4.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100008732","name":"Uehara Memorial Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008732","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020109","name":"Fukuoka Public Health Promotion Organization Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00405-026-10376-9","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T02:02:04Z","timestamp":1781488924000},"page":"5959-5969","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic impact of immune-related adverse events in recurrent or metastatic sinonasal squamous cell carcinoma treated with immune checkpoint inhibitors"],"prefix":"10.1007","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0395-8946","authenticated-orcid":false,"given":"Takahiro","family":"Hongo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Manako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Watanuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Masunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanobu","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriyasu","family":"Yamauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mioko","family":"Matsuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muneyuki","family":"Masuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"10376_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1038\/nrclinonc.2014.97","volume":"11","author":"JL Llorente","year":"2014","unstructured":"Llorente JL, Lopez F, Suarez C, Hermsen MA (2014) Sinonasal carcinoma: clinical, pathological, genetic and therapeutic advances. Nat Rev Clin Oncol 11:460\u2013472. https:\/\/doi.org\/10.1038\/nrclinonc.2014.97","journal-title":"Nat Rev Clin Oncol"},{"key":"10376_CR2","doi-asserted-by":"publisher","first-page":"2602","DOI":"10.1002\/cncr.28108","volume":"119","author":"B Ansa","year":"2013","unstructured":"Ansa B, Goodman M, Ward K, Kono SA, Owonikoko TK, Higgins K, Beitler JJ, Grist W, Wadsworth T, El-Deiry M, Chen AY, Khuri FR, Shin DM, Saba NF (2013) Paranasal sinus squamous cell carcinoma incidence and survival based on Surveillance, Epidemiology, and End Results data, 1973 to 2009. Cancer 119:2602\u20132610. https:\/\/doi.org\/10.1002\/cncr.28108","journal-title":"Cancer"},{"key":"10376_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14061463","volume":"14","author":"C Taverna","year":"2022","unstructured":"Taverna C, Agaimy A, Franchi A (2022) Towards a molecular classification of sinonasal carcinomas: clinical implications and opportunities. Cancers (Basel) 14:1463. https:\/\/doi.org\/10.3390\/cancers14061463","journal-title":"Cancers (Basel)"},{"key":"10376_CR4","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/PAS.0000000000001566","volume":"45","author":"T Hongo","year":"2021","unstructured":"Hongo T, Yamamoto H, Jiromaru R, Nozaki Y, Yasumatsu R, Hashimoto K, Yoneda R, Sugii A, Taguchi K, Masuda M, Nakagawa T, Oda Y (2021) Clinicopathologic significance of EGFR mutation and HPV infection in sinonasal squamous cell carcinoma. Am J Surg Pathol 45:108\u2013118. https:\/\/doi.org\/10.1097\/PAS.0000000000001566","journal-title":"Am J Surg Pathol"},{"key":"10376_CR5","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1177\/0003489420929048","volume":"129","author":"Z Al-Qurayshi","year":"2020","unstructured":"Al-Qurayshi Z, Smith R, Walsh JE (2020) Sinonasal squamous cell carcinoma presentation and outcome: a national perspective. Ann Otol Rhinol Laryngol 129:1049\u20131055. https:\/\/doi.org\/10.1177\/0003489420929048","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"10376_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/lary.24264","volume":"124","author":"S Sanghvi","year":"2014","unstructured":"Sanghvi S, Khan MN, Patel NR, Yeldandi S, Baredes S, Eloy JA (2014) Epidemiology of sinonasal squamous cell carcinoma: a comprehensive analysis of 4994 patients. Laryngoscope 124:76\u201383. https:\/\/doi.org\/10.1002\/lary.24264","journal-title":"Laryngoscope"},{"key":"10376_CR7","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/s0140-6736(19)32591-7","volume":"394","author":"B Burtness","year":"2019","unstructured":"Burtness B, Harrington KJ, Greil R, Souli\u00e8res D, Tahara M, de CastroPsyrri GA Jr, Bast\u00e9 N, Neupane P, Bratland \u00c5, Fuereder T, Hughes BGM, Mes\u00eda R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, Gonz\u00e1lez Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D (2019) Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 394:1915\u20131928. https:\/\/doi.org\/10.1016\/s0140-6736(19)32591-7","journal-title":"Lancet"},{"key":"10376_CR8","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","volume":"375","author":"RL Ferris","year":"2016","unstructured":"Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML (2016) Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 375:1856\u20131867. https:\/\/doi.org\/10.1056\/NEJMoa1602252","journal-title":"N Engl J Med"},{"key":"10376_CR9","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/s41379-021-00868-w","volume":"34","author":"T Hongo","year":"2021","unstructured":"Hongo T, Yamamoto H, Jiromaru R, Yasumatsu R, Kuga R, Nozaki Y, Hashimoto K, Matsuo M, Wakasaki T, Tamae A, Taguchi K, Toh S, Masuda M, Nakagawa T, Oda Y (2021) PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma. Mod Pathol 34:1966\u20131978. https:\/\/doi.org\/10.1038\/s41379-021-00868-w","journal-title":"Mod Pathol"},{"key":"10376_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.104776","volume":"109","author":"JC Park","year":"2020","unstructured":"Park JC, Faquin WC, Durbeck J, Faden DL (2020) Immune checkpoint inhibitors in sinonasal squamous cell carcinoma. Oral Oncol 109:104776. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.104776","journal-title":"Oral Oncol"},{"key":"10376_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17172872","volume":"17","author":"K Terazawa","year":"2025","unstructured":"Terazawa K, Kuroki M, Saijo K, Yamada T, Iinuma R, Kawaura R, Okuda H, Mori K, Shibata H, Utakata R, Umeda M, Ogawa T (2025) Immune checkpoint inhibitors in sinonasal squamous cell carcinoma: a retrospective study and literature review. Cancers (Basel) 17:2872. https:\/\/doi.org\/10.3390\/cancers17172872","journal-title":"Cancers (Basel)"},{"key":"10376_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s10147-020-01829-0","volume":"26","author":"N Hanai","year":"2021","unstructured":"Hanai N, Shimizu Y, Kariya S, Yasumatsu R, Yokota T, Fujii T, Tsukahara K, Yoshida M, Hanyu K, Ueda T, Hirakawa H, Takahashi S, Ono T, Sano D, Yamauchi M, Watanabe A, Omori K, Yamazaki T, Monden N, Kudo N, Arai M, Sakurai D, Asakage T, Doi I, Yamada T, Homma A (2021) Effectiveness and safety of nivolumab in patients with head and neck cancer in Japanese real-world clinical practice: a multicenter retrospective clinical study. Int J Clin Oncol 26:494\u2013506. https:\/\/doi.org\/10.1007\/s10147-020-01829-0","journal-title":"Int J Clin Oncol"},{"key":"10376_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07214-4","volume":"20","author":"H Kim","year":"2020","unstructured":"Kim H, Kwon M, Kim B, Jung HA, Sun JM, Lee SH, Park K, Ahn MJ (2020) Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. BMC Cancer 20:727. https:\/\/doi.org\/10.1186\/s12885-020-07214-4","journal-title":"BMC Cancer"},{"key":"10376_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2022.105932","volume":"130","author":"Y Ueda","year":"2022","unstructured":"Ueda Y, Okano S, Enokida T, Fujisawa T, Ito K, Sato M, Tanaka H, Wada A, Tahara M (2022) Nivolumab for recurrent or metastatic head and neck cancer patients with non-squamous cell carcinoma and\/or a primary subsite excluded from CheckMate141, a retrospective study. Oral Oncol 130:105932. https:\/\/doi.org\/10.1016\/j.oraloncology.2022.105932","journal-title":"Oral Oncol"},{"key":"10376_CR15","doi-asserted-by":"publisher","first-page":"3653","DOI":"10.21873\/anticanres.15854","volume":"42","author":"T Nakano","year":"2022","unstructured":"Nakano T, Yasumatsu R, Hashimoto K, Kuga R, Hongo T, Yamamoto H, Matsuo M, Wakasaki T, Jiromaru R, Manako T, Toh S, Masuda M, Yamauchi M, Kuratomi Y, Taura M, Takeuchi T, Nakagawa T (2022) Real-world experience with Pembrolizumab for advanced-stage head and neck cancer patients: a retrospective, multicenter study. Anticancer Res 42:3653\u20133664. https:\/\/doi.org\/10.21873\/anticanres.15854","journal-title":"Anticancer Res"},{"key":"10376_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2019.104525","volume":"101","author":"M Matsuo","year":"2019","unstructured":"Matsuo M, Yasumatsu R, Masuda M, Toh S, Wakasaki T, Hashimoto K, Taura M, Uchi R, Nakagawa T (2019) Relationship between immune-related adverse events and the long-term outcomes in recurrent\/metastatic head and neck squamous cell carcinoma treated with nivolumab. Oral Oncol 101:104525. https:\/\/doi.org\/10.1016\/j.oraloncology.2019.104525","journal-title":"Oral Oncol"},{"key":"10376_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101621","volume":"5","author":"H Yamaguchi","year":"2024","unstructured":"Yamaguchi H, Hsu JM, Sun L, Wang SC, Hung MC (2024) Advances and prospects of biomarkers for immune checkpoint inhibitors. Cell Rep Med 5:101621. https:\/\/doi.org\/10.1016\/j.xcrm.2024.101621","journal-title":"Cell Rep Med"},{"key":"10376_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"10376_CR19","doi-asserted-by":"publisher","first-page":"4073","DOI":"10.1200\/JCO.21.01440","volume":"39","author":"BJ Schneider","year":"2021","unstructured":"Schneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K (2021) Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 39:4073\u20134126. https:\/\/doi.org\/10.1200\/JCO.21.01440","journal-title":"J Clin Oncol"},{"key":"10376_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13061413","volume":"13","author":"I Vasiliadou","year":"2021","unstructured":"Vasiliadou I, Breik O, Baker H, Leslie I, Sim VR, Hegarty G, Michaelidou A, Nathan K, Hartley A, Good J, Sanghera P, Fong C, Guerrero Urbano T, Lei M, Petkar I, Reis Ferreira M, Nutting C, Wong KH, Newbold K, Harrington K, Bhide S, Kong A (2021) Safety and treatment outcomes of nivolumab for the treatment of recurrent or metastatic head and neck squamous cell carcinoma: retrospective multicenter cohort study. Cancers (Basel) 13:1413. https:\/\/doi.org\/10.3390\/cancers13061413","journal-title":"Cancers (Basel)"},{"key":"10376_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102134","volume":"92","author":"S Hussaini","year":"2021","unstructured":"Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, Fernandes R (2021) Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev 92:102134. https:\/\/doi.org\/10.1016\/j.ctrv.2020.102134","journal-title":"Cancer Treat Rev"},{"key":"10376_CR22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2016.1231292","volume":"5","author":"HO Ali","year":"2016","unstructured":"Ali HO, Diem S, Markert E, Jochum W, Kerl K, French LE, Speiser DE, Fr\u00fch M, Flatz L (2016) Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. Oncoimmunology 5:e1231292. https:\/\/doi.org\/10.1080\/2162402X.2016.1231292","journal-title":"Oncoimmunology"},{"key":"10376_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2020.105024","volume":"111","author":"JC Park","year":"2020","unstructured":"Park JC, Durbeck J, Clark JR, Faden DL (2020) Treatment sequence of cetuximab and immune checkpoint inhibitor in head and neck squamous cell carcinoma differentially affects outcomes. Oral Oncol 111:105024. https:\/\/doi.org\/10.1016\/j.oraloncology.2020.105024","journal-title":"Oral Oncol"},{"key":"10376_CR24","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1038\/s41379-022-01117-4","volume":"35","author":"YJ Kuo","year":"2022","unstructured":"Kuo YJ, Lewis JS Jr, Truong T, Yeh YC, Chernock RD, Zhai C, Chen YA, Hongo T, Lee CK, Shi Q, Velez Torres JM, Geromes AB, Chu YH, Hsieh MS, Yamamoto H, Weinreb I, Hang JF (2022) Nuclear expression of AFF2 C-terminus is a sensitive and specific ancillary marker for DEK::AFF2 carcinoma of the sinonasal tract. Mod Pathol 35:1587\u20131595. https:\/\/doi.org\/10.1038\/s41379-022-01117-4","journal-title":"Mod Pathol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-026-10376-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10376-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T02:03:24Z","timestamp":1791943404000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-026-10376-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10376"],"URL":"https:\/\/doi.org\/10.1007\/s00405-026-10376-9","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"3 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of the National Kyushu Cancer Center (2024\u201325) and Kyushu University (M25008). All procedures performed in this study were in accordance with the ethical standards of the institutional and national research committees and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for patient consent was waived due to the retrospective nature of this study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}